OncoMatch/Clinical Trials/NCT07145112
Laser Interstitial Thermal Therapy (LITT) and Lomustine (CCNU) for Recurrent Glioblastoma
Is NCT07145112 recruiting? Yes, currently enrolling (May 2026). This Phase 1 trial studies Lomustine for glioblastoma.
Treatment: Lomustine — This is a phase 1 study evaluating the safety and feasibility of laser interstitial thermal therapy (LITT) followed by lomustine (CCNU) for recurrent glioblastoma in adults. The primary aim is to evaluate the safety of the combination of LITT plus lomustine based on the assessment of treatment-related adverse events and the feasibility of completing LITT + lomustine in the proposed timeframe. The secondary aim is to assess overall survival for up to 2 years after the first dose of lomustine.
Check if I qualifyExtracted eligibility criteria
Cancer type
Glioblastoma
Prior therapy
Must have received: radiation therapy — for glioblastoma
Prior standard radiation for glioblastoma (short course 40 Gy, standard 60 Gy, and proton therapy are allowed).
Cannot have received: nitrosourea (lomustine, carmustine, nimustine)
Prior treatment with nitrosourea agents (e.g. lomustine [CCNU], carmustine [BCNU], nimustine [ACNU]).
Cannot have received: polifeprosan 20 with carmustine wafer
Prior treatment with polifeprosan 20 with carmustine wafer.
Cannot have received: VEGF inhibitor (bevacizumab)
Prior treatment with bevacizumab.
Cannot have received: investigational agent
Exception: if received ≤ 4 weeks or 5 drug half-lives (whichever is shorter) prior to commencing study treatment
Patients who have received any investigational agents ≤ 4 weeks or 5 drug half-lives (whichever is shorter) prior to commencing study treatment.
Lab requirements
Blood counts
WBC ≥ 3 × 10^9/L, ANC ≥ 1.5 × 10^9/L, platelet count ≥ 100 × 10^9/L, hemoglobin ≥ 9 gm/dL
Kidney function
calculated creatinine clearance ≥ 60 mL/min
Liver function
ALT (SGPT) and AST (SGOT) < 3× institutional ULN, alkaline phosphatase < 2× ULN, bilirubin < 1.5 mg/dL
adequate bone marrow function defined by: i. white blood cells (WBC) ≥ 3 × 10^9/L , ii. absolute neutrophil count (ANC) ≥ 1.5 × 10^9/L , iii. platelet count of ≥ 100 × 10^9/L , and iv. hemoglobin ≥ 9 gm/dL b. adequate liver function defined by i. alanine transaminase (ALT, SGPT) and aspartate transaminase (AST/SGOT) < 3× institutional upper limit of normal (ULN), ii. alkaline phosphatase < 2× ULN, and iii. bilirubin < 1.5 mg/dL c. adequate renal function defined by calculated creatinine clearance ≥ 60 mL/min
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- University of California Davis Comprehensive Cancer Center · Sacramento, California
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify